Involvement of CUL4A in regulation of multidrug resistance to P-gp substrate drugs in breast cancer cells

Molecules

Volumn 19, Issue 1, 2014, Pages 159-176

  Wang, Yunshan ^a,b   Ma, Guangxin ^a   Wang, Qin ^c   Wen, Mingxin ^a   Xu, Yangyang ^a   He, Xiuquan ^a   Zhang, Pengju ^d   Wang, Yuli ^a   Yang, Taomei ^a   Zhan, Panpan ^d   Wei, Guangwei ^a  

^a Shandong Key Laboratory of Digital Human and Clinical Anatomy   (China)

^b SHANDONG UNIVERSITY   (China)

^c SHANDONG UNIVERSITY   (China)

^d SHANDONG UNIVERSITY   (China)

Author keywords

Breast cancer; CUL4A; Multidrug resistant; P glycoprotein

Indexed keywords

EID: 84893073438     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules19010159     Document Type: Article

References (43)

1. Forouzanfar, M.H.; Foreman, K.J.; Delossantos, A.M.; Lozano, R.; Lopez, A.D.; Murray, C.J.; Naghavi, M. Breast and cervical cancer in 187 countries between 1980 and 2010: A systematic analysis. Lancet 2011, 378, 1461-1484.
2. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin. 2012, 62, 10-29.
3. Kuo, M.T. Roles of multidrug resistance genes in breast cancer chemoresistance. Adv. Exp. Med. Biol. 2007, 608, 23-30.
4. Taheri, M.; Mahjoubi, F.; Omranipour, R. Effect of MDR1 polymorphism on multidrug resistance expression in breast cancer patients. Genet. Mol. Res. 2010, 9, 34-40.
5. Wind, N.S.; Holen, I. Multidrug resistance in breast cancer: From in vitro models to clinical studies. Int. J. Breast Cancer. 2011, 2011, doi:10.4061/2011/967419.
6. Patwardhan, G.; Gupta, V.; Huang, J.; Gu, X.; Liu, Y.Y. Direct assessment of P-glycoprotein efflux to determine tumor response to chemotherapy. Biochem. Pharmacol. 2010, 80, 72-79.
7. Donmez, Y.; Gunduz, U. Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells. Biomed. Pharmacother. 2011, 65, 85-89.
8. Haber, M.; Bordow, S.B.; Haber, P.S.; Marshall, G.M.; Stewart, B.W.; Norris, M.D. The prognostic value of MDR1 gene expression in primary untreated neuroblastoma. Eur. J. Cancer 1997, 33, 2031-2036.
9. Norris, M.D.; Bordow, S.B.; Haber, P.S.; Marshall, G.M.; Kavallaris, M.; Madafiglio, J.; Cohn, S.L.; Salwen, H.; Schmidt, M.L.; Hipfner, D.R.; et al. Evidence that the MYCN oncogene regulates MRP gene expression in neuroblastoma. Eur. J. Cancer 1997, 33, 1911-1916.
10. Keppler, D. Multidrug resistance proteins (MRPs, ABCCs): Importance for pathophysiology and drug therapy. Handb. Exp. Pharmacol. 2011, 201, 299-323.
11. Kimura, Y.; Morita, S.Y.; Matsuo, M.; Ueda, K. Mechanism of multidrug recognition by MDR1/ABCB1. Cancer Sci. 2007, 98, 1303-1310.
12. Ludwig, J.A.; Szakacs, G.; Martin, S.E.; Chu, B.F.; Cardarelli, C.; Sauna, Z.E.; Caplen, N.J.; Fales, H.M.; Ambudkar, S.V.; Weinstein, J.N.; et al. Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res. 2006, 66, 4808-4815.
13. Chen, L.C.; Manjeshwar, S.; Lu, Y.; Moore, D.; Ljung, B.M.; Kuo, W.L.; Dairkee, S.H.; Wernick, M.; Collins, C.; Smith, H.S. The human homologue for the Caenorhabditis elegans cul-4 gene is amplified and overexpressed in primary breast cancers. Cancer Res. 1998, 58, 3677-3683.
14. Shiyanov, P.; Nag, A.; Raychaudhuri, P. Cullin 4A associates with the UV-damaged DNA-binding protein DDB. J. Biol. Chem. 1999, 274, 35309-35312.
15. Gupta, A.; Yang, L.X.; Chen, L. Study of the G2/M cell cycle checkpoint in irradiated mammary epithelial cells overexpressing Cul-4A gene. Int. J. Radiat. Oncol. Biol. Phys. 2002, 52, 822-830.
16. Li, B.; Yang, F.C.; Clapp, D.W.; Chun, K.T. Enforced expression of CUL-4A interferes with granulocytic differentiation and exit from the cell cycle. Blood 2003, 101, 1769-1776.
17. Sugasawa, K. DNA repair pathways involving Cul4A ubiquitin ligases. Tanpakushitsu Kakusan Koso. 2006, 51, 1339-1344.
18. Schindl, M.; Gnant, M.; Schoppmann, S.F.; Horvat, R.; Birner, P. Overexpression of the human homologue for Caenorhabditis elegans cul-4 gene is associated with poor outcome in node-negative breast cancer. Anticancer Res. 2007, 27, 949-952.
19. Ren, S.; Xu, C.; Cui, Z.; Yu, Y.; Xu, W.; Wang, F.; Lu, J.; Wei, M.; Lu, X.; Gao, X.; et al. Oncogenic CUL4A determines the response to thalidomide treatment in prostate cancer. J. Mol. Med. (Berl) 2012, 90, 1121-1132.
20. Panka, D.J.; Atkins, M.B.; Mier, J.W. Targeting the mitogen-Activated protein kinase pathway in the treatment of malignant melanoma. Clin. Cancer Res. 2006, 12, 2371S-2375S.
21. Johnson, G.L.; Lapadat, R. Mitogen-Activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002, 298, 1911-1912.
22. Yang, S.H.; Sharrocks, A.D.; Whitmarsh, A.J. MAP kinase signalling cascades and transcriptional regulation. Gene 2013, 513, 1-13.
23. Kohno, M.; Tanimura, S.; Ozaki, K. Targeting the extracellular signal-regulated kinase pathway in cancer therapy. Biol. Pharm. Bull. 2011, 34, 1781-1784.
24. Wei, F.; Yan, J.; Tang, D. Extracellular signal-regulated kinases modulate DNA damage response -A contributing factor to using MEK inhibitors in cancer therapy. Curr. Med. Chem. 2011, 18, 5476-5482.
25. Katayama, K.; Yoshioka, S.; Tsukahara, S.; Mitsuhashi, J.; Sugimoto, Y. Inhibition of the mitogen-Activated protein kinase pathway results in the down-regulation of P-glycoprotein. Mol. Cancer Ther. 2007, 6, 2092-2102.
26. Kisucka, J.; Barancik, M.; Bohacova, V.; Breier, A. Reversal effect of specific inhibitors of extracellular-signal regulated protein kinase pathway on P-glycoprotein mediated vincristine resistance of L1210 cells. Gen. Physiol. Biophys. 2001, 20, 439-444.
27. Lin, J.C.; Chang, S.Y.; Hsieh, D.S.; Lee, C.F.; Yu, D.S. Modulation of mitogen-Activated protein kinase cascades by differentiation-1 protein: Acquired drug resistance of hormone independent prostate cancer cells. J. Urol. 2005, 174, 2022-2026.
28. Li, Y.; Li, S.; Han, Y.; Liu, J.; Zhang, J.; Li, F.; Wang, Y.; Liu, X.; Yao, L. Calebin-A induces apoptosis and modulates MAPK family activity in drug resistant human gastric cancer cells. Eur. J. Pharmacol. 2008, 591, 252-258.
29. McCubrey, J.A.; Steelman, L.S.; Chappell, W.H.; Abrams, S.L.; Wong, E.W.; Chang, F.; Lehmann, B.; Terrian, D.M.; Milella, M.; Tafuri, A.; et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta 2007, 1773, 1263-1284.
30. Higa, L.A.; Wu, M.; Ye, T.; Kobayashi, R.; Sun, H.; Zhang, H. CUL4-DDB1 ubiquitin ligase interacts with multiple WD40-repeat proteins and regulates histone methylation. Nat. Cell. Biol. 2006, 8, 1277-1283.
31. Di Cosimo, S.; Baselga, J. Management of breast cancer with targeted agents: Importance of heterogeneity [corrected]. Nat. Rev. Clin. Oncol. 2010, 7, 139-147.
32. Li, Q.Q.; Wang, W.J.; Xu, J.D.; Cao, X.X.; Chen, Q.; Yang, J.M.; Xu, Z.D. Involvement of CD147 in regulation of multidrug resistance to P-gp substrate drugs and in vitro invasion in breast cancer cells. Cancer Sci. 2007, 98, 1064-1069.
33. Xu, J.W.; Li, Q.Q.; Tao, L.L.; Cheng, Y.Y.; Yu, J.; Chen, Q.; Liu, X.P.; Xu, Z.D. Involvement of EGFR in the promotion of malignant properties in multidrug resistant breast cancer cells. Int. J. Oncol. 2011, 39, 1501-1509.
34. Amiri-Kordestani, L.; Basseville, A.; Kurdziel, K.; Fojo, A.T.; Bates, S.E. Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist. Updat. 2012, 15, 50-61.
35. Borowski, E.; Bontemps-Gracz, M.M.; Piwkowska, A. Strategies for overcoming ABC-transportersmediated multidrug resistance (MDR) of tumor cells. Acta Biochim. Pol. 2005, 52, 609-627.
36. Hung, M.S.; Mao, J.H.; Xu, Z.; Yang, C.T.; Yu, J.S.; Harvard, C.; Lin, Y.C.; Bravo, D.T.; Jablons, D.M.; You, L. Cul4A is an oncogene in malignant pleural mesothelioma. J. Cell. Mol. Med. 2011, 15, 350-358.
37. Lee, J.; Zhou, P. Pathogenic role of the CRL4 ubiquitin ligase in human disease. Front. Oncol. 2012, 2, doi:10.3389/fonc.2012.00021.
38. Yan, F.; Wang, X.M.; Pan, C.; Ma, Q.M. Down-regulation of extracellular signal-regulated kinase 1/2 activity in P-glycoprotein-mediated multidrug resistant hepatocellular carcinoma cells. World J. Gastroenterol. 2009, 15, 1443-1451.
39. Nag, A.; Bagchi, S.; Raychaudhuri, P. Cul4A physically associates with MDM2 and participates in the proteolysis of p53. Cancer Res. 2004, 64, 8152-8155.
40. Bondar, T.; Kalinina, A.; Khair, L.; Kopanja, D.; Nag, A.; Bagchi, S.; Raychaudhuri, P. Cul4A and DDB1 associate with Skp2 to target p27Kip1 for proteolysis involving the COP9 signalosome. Mol. Cell. Biol. 2006, 26, 2531-2539.
41. Nishitani, H.; Shiomi, Y.; Iida, H.; Michishita, M.; Takami, T.; Tsurimoto, T. CDK inhibitor p21 is degraded by a proliferating cell nuclear antigen-coupled Cul4-DDB1Cdt2 pathway during S phase and after UV irradiation. J. Biol. Chem. 2008, 283, 29045-29052.
42. El-Mahdy, M.A.; Zhu, Q.; Wang, Q.E.; Wani, G.; Praetorius-Ibba, M.; Wani, A.A. Cullin 4A-mediated proteolysis of DDB2 protein at DNA damage sites regulates in vivo lesion recognition by XPC. J. Biol. Chem. 2006, 281, 13404-13411.
43. Ang, Y.S.; Tsai, S.Y.; Lee, D.F.; Monk, J.; Su, J.; Ratnakumar, K.; Ding, J.; Ge, Y.; Darr, H.; Chang, B.; et al. Wdr5 mediates self-renewal and reprogramming via the embryonic stem cell core transcriptional network. Cell 2011, 145, 183-197.